期刊文献+

血管性血友病因子裂解酶在肾病综合征患者血浆中的变化及其临床意义 被引量:3

Clinical Significance of ADAMTS13 in Patients with Nephrotic Syndrome
原文传递
导出
摘要 目的检测血管性血友病因子裂解酶(vWF-cp,亦称ADAMTS13)与血管性血友病因子(vWF)在肾病综合征(NS)患者血浆中的抗原水平并探讨其临床意义。方法将70例NS患者分为膜性肾病(MN)组和非膜性肾病(non-MN)组,用ELISA法检测MN组、non-MN组和正常对照组血浆ADAMTS13和vWF抗原,比较各组间AD-AMTS13抗原、vWF抗原及vWF/ADAMTS13比值的差异及其与临床指标的关系。结果 (1)与正常对照组相比,两组患者血浆ADAMTS13抗原均明显降低(均P<0.05),而vWF抗原均明显升高(均P<0.05)。vWF/ADAMTS13比值在3组间两两比较,差异均有高度统计学意义(均P<0.01)。(2)相关分析显示,NS患者血浆ADAMTS13抗原与血清总蛋白(TP)、血清白蛋白(ALB)成正相关(均P<0.01),与24 h尿蛋白、甘油三酯(TG)、总胆固醇(TC)成负相关(P<0.05或0.01);血浆vWF抗原与TP、ALB成负相关,与24 h尿蛋白、TG、血浆纤维蛋白原、D-二聚体成正相关(P<0.05或0.01);血浆ADAMTS13抗原与vWF抗原之间无明显相关性(P>0.05)。结论血浆AD-AMTS13抗原水平低下、ADAMTS13和vWF抗原比例失衡可能是NS形成血栓的重要机制之一。 Objective To detect the antigen levels of von Willebrand factor cleaving protease(vWF-cp,also known as ADAMTS13) and von Willebrand factor(vWF) in plasma of patients with nephritic syndrome(NS) and investigate its clinical significance.Methods A total of 70 NS patients were enrolled in the study.They were divided into the membranous nephropathy(MN) group and non-membranous nephropathy(non-MN) group.In MN group and non-MN group as well as the control group,the plasma ADANTS13 antigens and vWF antigens in both patients and normal controls were assayed by ELISA assay.The differences of plasma ADAMTS13 antigen,vWF antigen and ratio of vWF to ADAMTS13 were compared in the three groups and the correlation relation was analyzed among ADAMTS13 antigen,vWF antigen and other clinical indexes.Results(1) Compared with normal control group,plasma ADAMTS13 antigens of both MN group and non-MN group decreased(all P0.05),vWF antigens increased(all P0.05),and the ratios of VWF antigen to ADAMTS13 antigen increased too(all P0.01).(2) Correlation analysis showed that plasma ADAMTS13 antigen of patients with NS was positively correlated with the serum total protein(TP) and albumin(ALB),while negatively correlated with the quantitative measurement of 24 hours urinary protein,total cholesterol(TC) and triglyceride(TG);plasma vWF antigen was negatively correlated with TP and ALB,and positively correlated with fibrinogen and D-Dimer;there was no significant correlation among plasma ADAMTS13 antigen and vWF antigen.Conclusion The deficiency of plasma ADAMTS13 antigens,and the disbalance of ADAMTS13 and vWF may be one of the mechanism of the thrombosis which is a common complication of nephritic syndrome.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2011年第2期294-297,300,共5页 Suzhou University Journal of Medical Science
关键词 肾病综合征 血管性血友病因子裂解酶 血管性血友病因子 nephritic syndrome ADAMTS13 von Willebrand factor
  • 相关文献

参考文献1

二级参考文献7

  • 1Tam LS,Li EK,Leung VY,et al.Effects of vitamin C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus:a double blind,placebo controlled pilot study.J Rheumatol,2005,32:275-282.
  • 2Yoo G,Blomback M,Schenck-Gustafsson K,et al.Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocy-topenic purpure:study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.Br J Haematol,2003,121:123-129.
  • 3Weening JJ,D′Agati VD,Schwartz MM,et al.The classification of glomerulone-phritis in systemic lupus erythematosus revisited.Kidney Int,2004,65:521-530.
  • 4Rick ME,Moll S,Taylor MA.Clinical use of rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura.Thromb Haemost,2002,88:598-604.
  • 5Bombardier C,Ladman DD,Urowitz MB,et al.Derivation of the SLEDAI:a disease activity index for lupus patients.The Committee on Prognosis Studies in SLE.Arthritis Rheum,1992,35:630-640.
  • 6Mannucci PM,Vanoli M,Forza I,et al.von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue dieases(systemic lupus erythematosus and systemic sclerosis).Haematologica,2003,88:914-918.
  • 7Rieger M,Mannucci PM,Kremer Hovinga JA,et al.ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.Blood,2005,106:1262-1267.

共引文献1

同被引文献21

  • 1叶任高.内科学[M]5版[M].北京:人民卫生出版社,2000.961.
  • 2Margaret E Rick, Stephan Moll,Mark A Taylor,et al. Clinical use of a rapid collagen binding assay for yon Willebrand factor cleaaaving protease in patients with thromboeytopenic purpura[J]. ThrombHaemost, 2002,88 : 598-604.
  • 3Fiehtlseherer S, Rosenberer G, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation, 2000,102 : 1000-1006.
  • 4Bhgat K, Valance P. Inflammatory cytokines impair endothelium dependent dilation in human veins in vivo[J]. Circulation, 1997, 96 : 3042-3047.
  • 5Lowenstein C j, Morrell CN,Yamakuchi M. Regulation of Weibel- Palade Body Exocytosis[J]. Semin Vasc Med, 2005 : 15 : 302-308.
  • 6Fujikawa K, Suzuki H, McMullen B, et al. Purification of human yon Willebrand factor - cleaving protease and its identification as a new member of the metalloproteinase family [J]. Blood, 2001,98 (6) :1662 - 1666.
  • 7Yoo G, Blomback M, Sehenck - Gustafsson K, et al. Decreased levels of yon Willebrand factor - cleaving protease in coronary heart disease and thrombotic thromobocytopenic purpura: study of a sim- plified method for assaying the enzyme activity based on ristocetin - induced platelet aggregation [ J]. Br J Haematol, 2003,121 ( 1 ) : 123 - 129.
  • 8Claus RA, Bockmeyer CL, Sossdorf M, et al. The balance be- tween yon - Willebrand factor and its cleaving protease AD- AMTS13 : biomarker in systemic inflammation and development of organ failure? [Jl. Curr Mol Med, 2010,10(2) :236 -248.
  • 9Chion CK, Doggen CJ, Crawley JT, et al. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men [J]. Blood. 2007.109(5):1998 -2000.
  • 10Meade TW, Cooper JA, Stirling Y, et al. Factor Ⅷ, ABO blood group and the incidence of ischemic heart disease [ J ]. Br J Haematol, 1994,88 (3) :601 - 607.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部